The Global Initiative for Obstructive Sleep Apnea (GIFOSA): Rationale, Strategic Framework, and Call to Action.

IF 3.4 Q2 RESPIRATORY SYSTEM

Pulmonary Therapy Pub Date : 2026-09-21 DOI:10.1007/s41030-026-00386-7

Sy Duong-Quy, Naricha Chirakalwasan, Tayard Desudchit, Stanley Yung-Chuan Liu, Leow Leong Chai, Thien Thanh Dang-Vu, Hiroshi Kadotani, Sang-Ha Kim, Hyung Chae Yang, Rodolfo V Dizon, Ravi Gupta, Allen Widysanto, Rusdi Bin Abd Rashid, Yap Yoke Yeow, Jianchen Cui, Mohammed A Al-Abri, Mouhamad Ghyath Jamil, Hamza Dhafar, Babak Amra, Pei-Lin Lee, Kiong Fou Yoom, Glenn Roldan, Carlos Teixeira, Kouassi Boko Alexandre, Amine Benjelloun, Franck-Hardain Okemba-Okombi, Chan Sarin, Thai Nguyen-Duy, Dung Nguyen-Thi-Thu, Huong Le-Thi-Minh, Thuy Tran-Phan-Chung, Linh Pham-Van, Giap Vu-Van, Vinh Nguyen-Nhu, Bao Le-Khac, Nhung Nguyen-Viet, Franck Soyez, Véronique Bricout, Fannie Onen, Francis Martin, Ahmed BaHammam, Thomas Penzel, Timothy Craig, Clete Kushida

{"title":"The Global Initiative for Obstructive Sleep Apnea (GIFOSA): Rationale, Strategic Framework, and Call to Action.","authors":"Sy Duong-Quy, Naricha Chirakalwasan, Tayard Desudchit, Stanley Yung-Chuan Liu, Leow Leong Chai, Thien Thanh Dang-Vu, Hiroshi Kadotani, Sang-Ha Kim, Hyung Chae Yang, Rodolfo V Dizon, Ravi Gupta, Allen Widysanto, Rusdi Bin Abd Rashid, Yap Yoke Yeow, Jianchen Cui, Mohammed A Al-Abri, Mouhamad Ghyath Jamil, Hamza Dhafar, Babak Amra, Pei-Lin Lee, Kiong Fou Yoom, Glenn Roldan, Carlos Teixeira, Kouassi Boko Alexandre, Amine Benjelloun, Franck-Hardain Okemba-Okombi, Chan Sarin, Thai Nguyen-Duy, Dung Nguyen-Thi-Thu, Huong Le-Thi-Minh, Thuy Tran-Phan-Chung, Linh Pham-Van, Giap Vu-Van, Vinh Nguyen-Nhu, Bao Le-Khac, Nhung Nguyen-Viet, Franck Soyez, Véronique Bricout, Fannie Onen, Francis Martin, Ahmed BaHammam, Thomas Penzel, Timothy Craig, Clete Kushida","doi":"10.1007/s41030-026-00386-7","DOIUrl":null,"url":null,"abstract":"<p><p>Obstructive sleep apnea (OSA) is one of the most prevalent chronic sleep disorders worldwide, affecting an estimated nearly one billion adults globally, and is increasingly recognized as a major contributor to cardiometabolic disease, impaired quality of life, and escalating healthcare costs. Despite substantial advances in understanding OSA pathophysiology, diagnosis, and treatment, significant disparities persist in access to care, implementation of evidence-based practice, and long-term outcomes across regions and healthcare systems. The Global Initiative for Obstructive Sleep Apnea (GIFOSA) was established as an implementation-focused initiative to address these challenges through a coordinated, multidisciplinary framework that goes beyond existing regional and national efforts by integrating global coordination, action-oriented implementation strategies, practical tools, and policy engagement. This paper presents the conceptual foundations of GIFOSA and outlines its strategic pillars: strengthening clinical and scientific foundations, building workforce capacity, advancing person-centered management, and integrating OSA into population health and policy agendas. Central to its pragmatic structure is a focus on implementation feasibility, including context-sensitive care pathways, task-sharing approaches, and technology-enabled diagnostics and management strategies that can be adopted across resource levels. By emphasizing cross-disciplinary collaboration, technological innovation, and alignment with health systems and policy priorities, GIFOSA seeks to bridge the gap between knowledge and practice while promoting equitable access to diagnosis and treatment. The initiative further highlights the importance of prevention, digital health integration, and global research collaboration to support sustainable and measurable improvements in OSA care worldwide.Graphical Abstract is available with this article.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41030-026-00386-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Obstructive sleep apnea (OSA) is one of the most prevalent chronic sleep disorders worldwide, affecting an estimated nearly one billion adults globally, and is increasingly recognized as a major contributor to cardiometabolic disease, impaired quality of life, and escalating healthcare costs. Despite substantial advances in understanding OSA pathophysiology, diagnosis, and treatment, significant disparities persist in access to care, implementation of evidence-based practice, and long-term outcomes across regions and healthcare systems. The Global Initiative for Obstructive Sleep Apnea (GIFOSA) was established as an implementation-focused initiative to address these challenges through a coordinated, multidisciplinary framework that goes beyond existing regional and national efforts by integrating global coordination, action-oriented implementation strategies, practical tools, and policy engagement. This paper presents the conceptual foundations of GIFOSA and outlines its strategic pillars: strengthening clinical and scientific foundations, building workforce capacity, advancing person-centered management, and integrating OSA into population health and policy agendas. Central to its pragmatic structure is a focus on implementation feasibility, including context-sensitive care pathways, task-sharing approaches, and technology-enabled diagnostics and management strategies that can be adopted across resource levels. By emphasizing cross-disciplinary collaboration, technological innovation, and alignment with health systems and policy priorities, GIFOSA seeks to bridge the gap between knowledge and practice while promoting equitable access to diagnosis and treatment. The initiative further highlights the importance of prevention, digital health integration, and global research collaboration to support sustainable and measurable improvements in OSA care worldwide.Graphical Abstract is available with this article.

查看原文本刊更多论文

阻塞性睡眠呼吸暂停全球倡议（GIFOSA）：理论基础、战略框架和行动呼吁。

阻塞性睡眠呼吸暂停（OSA）是世界上最普遍的慢性睡眠障碍之一，影响着全球近10亿成年人，并且越来越被认为是导致心脏代谢疾病、生活质量受损和医疗成本上升的主要因素。尽管在了解OSA病理生理、诊断和治疗方面取得了实质性进展，但在获得护理、循证实践的实施以及不同地区和医疗保健系统的长期结果方面仍然存在显著差异。阻塞性睡眠呼吸暂停全球倡议（GIFOSA）是一项以实施为重点的倡议，旨在通过一个协调的多学科框架，超越现有的区域和国家努力，通过整合全球协调、以行动为导向的实施战略、实用工具和政策参与，应对这些挑战。本文介绍了GIFOSA的概念基础，并概述了其战略支柱：加强临床和科学基础，建设劳动力能力，推进以人为本的管理，并将OSA纳入人口健康和政策议程。其务实结构的核心是对实施可行性的关注，包括上下文敏感的护理途径、任务共享方法以及可跨资源级别采用的技术支持诊断和管理策略。通过强调跨学科合作、技术创新以及与卫生系统和政策重点保持一致，GIFOSA力求弥合知识与实践之间的差距，同时促进公平获得诊断和治疗。该倡议进一步强调了预防、数字健康整合和全球研究合作的重要性，以支持全球OSA护理的可持续和可衡量的改善。本文提供了图形摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonary Therapy Medicine-Pulmonary and Respiratory Medicine

CiteScore

5.20

自引率

3.30%

发文量

审稿时长

6 weeks

期刊介绍： Aims and Scope Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques. Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies. Open Access All articles published by Pulmonary Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Pulmonary Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €4500/ $5100/ £3650. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Pulmonary Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.